Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life Sciences from the LSP Dementia Fund, together with age1 and participation from laso Ventures,...
Hence then, the article about eqt life sciences co leads usd 39 million series a in aerska to help systematically deliver rna medicines to the brain was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain )
Also on site :
- Europe’s cyber agency blames hacking gangs for massive data breach and leak
- The Trump Dictatorship Is Cracking Up
- Miami lands blue-chip quarterback for 2027 class